Dupont Capital Management Corp acquired a new stake in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) during the third quarter, according to its most recent filing with the SEC. The firm acquired 53,851 shares of the biopharmaceutical company’s stock, valued at approximately $635,000. Dupont Capital Management Corp owned about 0.12% of Sucampo Pharmaceuticals as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Krensavage Asset Management LLC boosted its position in Sucampo Pharmaceuticals by 0.6% in the 2nd quarter. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company’s stock valued at $29,607,000 after buying an additional 16,570 shares during the last quarter. LSV Asset Management boosted its position in Sucampo Pharmaceuticals by 1.9% in the 2nd quarter. LSV Asset Management now owns 2,390,418 shares of the biopharmaceutical company’s stock valued at $25,099,000 after buying an additional 44,000 shares during the last quarter. Vanguard Group Inc. boosted its position in Sucampo Pharmaceuticals by 13.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock valued at $17,287,000 after buying an additional 189,561 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Sucampo Pharmaceuticals by 1.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock valued at $16,487,000 after buying an additional 15,528 shares during the last quarter. Finally, NEA Management Company LLC bought a new position in Sucampo Pharmaceuticals in the 2nd quarter valued at $13,214,000. Hedge funds and other institutional investors own 55.76% of the company’s stock.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at $10.70 on Friday. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. The firm has a market capitalization of $498.11, a PE ratio of 7.33, a price-to-earnings-growth ratio of 3.21 and a beta of 1.38. Sucampo Pharmaceuticals, Inc. has a twelve month low of $9.30 and a twelve month high of $17.55.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.30 earnings per share. equities analysts predict that Sucampo Pharmaceuticals, Inc. will post 1.11 EPS for the current year.
A number of brokerages have commented on SCMP. BidaskClub lowered Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 5th. Mizuho lowered Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $14.00 to $12.00 in a research report on Tuesday, October 3rd. UBS AG reduced their price target on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, October 12th. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Finally, Maxim Group restated a “buy” rating and issued a $23.00 price target (up from $21.00) on shares of Sucampo Pharmaceuticals in a research report on Tuesday, August 8th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $16.50.
WARNING: “Dupont Capital Management Corp Acquires Shares of 53,851 Sucampo Pharmaceuticals, Inc. (SCMP)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/11/12/dupont-capital-management-corp-acquires-shares-of-53851-sucampo-pharmaceuticals-inc-scmp.html.
In other Sucampo Pharmaceuticals news, major shareholder Sachiko Kuno sold 1,000,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Jason Patrick Meyenburg purchased 4,000 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was purchased at an average cost of $12.13 per share, for a total transaction of $48,520.00. Following the purchase, the insider now directly owns 30,228 shares in the company, valued at $366,665.64. The disclosure for this purchase can be found here. Insiders own 4.13% of the company’s stock.
Sucampo Pharmaceuticals Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.